Waiting times do not negatively modify outcome of patients with multiform glioblastoma;Les délais au diagnostic et à la mise en traitement n'altèrent pas les résultats des traitements délivrés aux patients atteints de glioblastome

Cancer/Radiotherapie

Volumn 13, Issue 1, 2009, Pages 17-23

  Noel G ^a   Quetin, P ^a   Heymann, S ^a   Karamanoukian, D ^a   Schott, R ^a  

^a CENTRE PAUL STRAUSS   (France)

Author keywords

Glioblastoma; Radiotherapy; Waiting time

Indexed keywords

CARMUSTINE; CISPLATIN; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOSURGERY; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; SCHOOL CHILD; THREE DIMENSIONAL IMAGING;

EID: 58249135636     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2008.10.002     Document Type: Article

References (29)

1. Barton M.B., Morgan G., Smee R., Tiver K.W., Hamilton C., and Gebski V. Does waiting time affect the outcome of larynx cancer treated by radiotherapy?. Radiother Oncol 44 (1997) 137-141
2. Blankenberg F.G., Teplitz R.L., Ellis W., Salamat M.S., Min B.H., Hall L., et al. The influence of volumetric tumor doubling time, DNA ploidy, and histologic grade on the survival of patients with intracranial astrocytomas. Am J Neuroradiol 16 (1995) 1001-1012
3. Boisserie G., and Hasboun D. Utilisation de l'imagerie multimodalité en radiothérapie. Cancer Radiother 5 (2001) 15s-35s
4. Bolla M., Mazeron J.J., Mornex F., and Eschwege F. Les actions de la Société française de radiothérapie oncologique (SFRO), dans le contexte du Plan cancer et des événements récents de radioprotection. Cancer Radiother 11 (2007) 305-308
5. Burnet N.G., Jena R., Jefferies S.J., Stenning S.P., and Kirkby N.F. Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. Clin Oncol (R Coll Radiol) 18 (2006) 93-103
6. Chen Z., King W., Pearcey R., Kerba M., and Mackillop W.J. The relationship between waiting time for radiotherapy and clinical outcomes: A systematic review of the literature. Radiother Oncol 87 (2008) 3-16
7. Do V., Gebski V., and Barton M.B. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol 57 (2000) 131-136
8. Erridge S.C., Porter H.Q., Rugg L.J., Wilson A., Kehoe T., Redpath T., et al. Reducing waiting times: a whole department approach. Clin Oncol (R Coll Radiol) 19 (2007) S9
9. Gonzalez-SanSegundo C., Santos-Miranda J.A., and Cuesta-Alvaro P. Comment on: The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol 60 (2001) 333-334
10. Hansen O., Larsen S., Bastholt L., Godballe C., and Jorgensen K.E. Duration of symptoms: impact on outcome of radiotherapy in glottic cancer patients. Int J Radiat Oncol Biol Phys 61 (2005) 789-794
11. Irwin C., Hunn M., Purdie G., and Hamilton D. Delay in radiotherapy shortens survival in patients with high grade glioma. J Neuro Oncol 85 (2007) 339-343
12. Lee A.W., Chan D.K., Fowler J.F., Poon Y.F., Law S.C., Foo W., et al. T1 nasopharyngeal carcinoma: the effect of waiting time on tumor control. Int J Radiat Oncol Biol Phys 30 (1994) 1111-1117
13. Lopez S., Calugaru V., Lamproglou I.C.B., Boscos C., Taillibert S., Simon J.M., et al. Les effets de la liste d'attente sur la survie des patients atteints de glioblastome traité par irradiation. Cancer Radiother 12 (2008) 497-499
14. Mackillop W.J. Killing time: the consequences of delays in radiotherapy. Radiother Oncol 84 (2007) 1-4
15. Mackillop W.J., Fu H., Quirt C.F., Dixon P., Brundage M., and Zhou Y. Waiting for radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 30 (1994) 221-228
16. Noël G., Feuvret L., Simon J.M., Chossière L., Boisserie G., Mazeron J.J., et al. Glioblastomes multiformes traités par chirurgie, radiothérapie postopératoire avec ou sans chimiothérapie. Analyse rétrospective de la survie en fonction des paramètres cliniques et thérapeutiques. À propos de 133 cas. In : Baillet F. Tumeur du système nerveux (eds) (1999), DYK, Paris p. 7-19
17. Norden A.D., Young G.S., Setayesh K., Muzikansky A., Klufas R., Ross G.L., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008) 779-787
18. Perry J., Chambers A., Spithoff K., and Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 14 (2007) 189-194
19. Primdahl H., Nielsen A.L., Larsen S., Andersen E., Ipsen M., Lajer C., et al. Changes from 1992 to 2002 in the pretreatment delay for patients with squamous cell carcinoma of larynx or pharynx: a Danish nationwide survey from DAHANCA. Acta Oncol 45 (2006) 156-161
20. Richards M.A., Westcombe A.M., Love S.B., Littlejohns P., and Ramirez A.J. Influence of delay on survival in patients with breast cancer: A systematic review. Lancet 353 (1999) 1119-1126
21. Roa W., Brasher P.M., Bauman G., Anthes M., Bruera E., Chan A., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 22 (2004) 1583-1588
22. Ruggieri-Pignon S., Pignon T., Marty M., Rodde-Dunet M.H., Destembert B., and Fritsch B. Infrastructure of radiation oncology in France: a large survey of evolution of external beam radiotherapy practice. Int J Radiat Oncol Biol Phys 61 (2005) 507-516
23. Schlienger M. Délais et retards à la radiothérapie : réflexion à propos de trois types de tumeurs. Cancer Radiother 9 (2005) 590-601
24. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
25. Thomson C.L., Watterson A., Pritchard C., and Thomson A.H. Effects of waiting times and adjuvant chemotherapy in patients with glioblastoma multiforme. Clin Oncol (R Coll Radiol) 19 (2007) S47-S48
26. Tsuboi K., Yoshii Y., Nakagawa K., and Maki Y. Regrowth patterns of supratentorial gliomas: Estimation from computed tomographic scans. Neurosurgery 19 (1986) 946-951
27. Vredenburgh J.J., Desjardins A., Herndon II J.E., Marcello J., Reardon D.A., Quinn J.A., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729
28. Waaijer A., Terhaard C.H., Dehnad H., Hordijk G.J., van Leeuwen M.S., Raaymakers C.P., et al. Waiting times for radiotherapy: consequences of volume increase for the TCP in oropharyngeal carcinoma. Radiother Oncol 66 (2003) 271-276
29. Woynar S., Debouck F., Cellier P., Bourhis J., Cauterman M., and Lartigau E. Vers une « politique sécurité » en oncologie-radiothérapie. La mise en œuvre du retour d'expérience. Cancer Radiother 11 (2007) 320-328